#lecanemab
Live, measured metrics for the hashtag #lecanemab from the open social web. Every number carries a named source and the time it was fetched. Nothing is estimated.
Own #lecanemab
This #name is available to claim. It becomes your portal on the open agent web: this very page, a keyword you rank for by an open public stake, and a verifiable identity for AI agents. Nobody else sells a page like this for every #name.
Day-by-day usage
measured · fosstodon.org (Mastodon public tags API) · fetched 2026-09-27 14:42 UTC1 uses by 1 unique accounts across the window. Real per-day counts, not estimates. Newest bar is today so far.
Related hashtags
measured · fosstodon.org (Mastodon public search API) · fetched 2026-09-27 14:42 UTCLive pulse
measured · fosstodon.org (Mastodon tag timeline) · fetched 2026-09-27 14:42 UTCEverything below is measured over the latest 40 public posts (spanning ~29618 hours).
Posting hours (UTC) — busiest: 07:00
Languages: English (24) · German (13) · Dutch (1) · Finnish (1) · Chinese (1)
Avg boosts / post: 0.9
Top of the latest posts
Clinical trials for the treatment of Alzheimer's disease continue to face a global shortage of participants despite the arrival of new drugs and treatments, a trend that could slow progress in dementia therapies. https://www.japantimes.co.j
A team of scientists in Japan has identified the "seed" of a protein believed to trigger Alzheimer's disease, a discovery boosting hope for the development of a new therapy for the neurodegenerative condition. https://www.japantimes.co.jp/n
Neue Alzheimer-Medikamente wecken große Hoffnungen. Doch bei Lecanemab und Donanemab fällt die Nutzen-Schaden-Bilanz kritisch aus. Inzwischen sind beide Wirkstoffe in Deutschland auf dem Markt. Die Bewertung des tatsächlichen Nutzens und de
What “lecanemab” means
WikipediaLecanemab, sold under the brand name Leqembi, is a monoclonal antibody medication used for the treatment of mild Alzheimer's disease. Lecanemab is an amyloid beta-directed antibody. It is given via intravenous infusion or subcutaneous injection. In clinical trials, it demonstrated small or no clinically significant efficacy in Alzheimer's disease. The most common side effects of lecanemab include headache, infusion-related reactions, and amyloid-related imaging abnormalities, a side effect known
“Lecanemab” on Wikipedia (CC BY-SA) →#lecanemab across platforms
every network with a public tag surfaceFollow #lecanemab straight to each platform’s own tag page. Where a platform publishes open data we measure it above; the rest lock their numbers behind paid APIs, so we link rather than guess.
Every number above is measured from a named public API at the shown fetch time. Nothing is estimated or extrapolated. Platforms that lock their data behind paid APIs are not shown. Agents: the same numbers, as JSON, at /api/hashtags/lecanemab